Loading…
Celiac Disease and Celiac Antibodies in DM1 Patients: When Are Screening and Biopsy Recommended?
Introduction The prevalence of celiac disease (CD) is increased in diabetes mellitus type 1 (DM1) patients. In most cases, CD is diagnosed in asymptomatic patients and hence periodic screening tests are recommended, but the timing, frequency of tests and indication for duodenal biopsy is unclear. Th...
Saved in:
Published in: | Digestive diseases and sciences 2019-02, Vol.64 (2), p.487-492 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c438t-a9c381dd78053d2ca24bec618692767f60725103669e9d9d4f6222f23503a06a3 |
---|---|
cites | cdi_FETCH-LOGICAL-c438t-a9c381dd78053d2ca24bec618692767f60725103669e9d9d4f6222f23503a06a3 |
container_end_page | 492 |
container_issue | 2 |
container_start_page | 487 |
container_title | Digestive diseases and sciences |
container_volume | 64 |
creator | Slae, Mordechai Romem, Azi Edri, Shalom Toker, Ori Wilschanski, Michael Strich, David |
description | Introduction
The prevalence of celiac disease (CD) is increased in diabetes mellitus type 1 (DM1) patients. In most cases, CD is diagnosed in asymptomatic patients and hence periodic screening tests are recommended, but the timing, frequency of tests and indication for duodenal biopsy is unclear. The purpose of this study was to investigate the dynamics of CD serology in DM1 and identify risk factors for CD.
Methods
Celiac serology and duodenal biopsy results from 1990 until 2015 were collected from patients with DM1. The outcome of positive celiac serology, the incidence and risk factors for CD in DM1 patients were investigated.
Results
A total of 314 DM1 patients who had celiac serology were identified, with follow-up period up to 23 years. Of 31 patients (9.9%) with positive celiac serology, 11(35.4%) had spontaneous normalization after various time periods. Eighteen patients were diagnosed with CD (58.1% of positive celiac serology, 5.73% of the study cohort). Age under 4.5 years was a risk factor for CD, but not family background of autoimmune diseases or gender. All patients with CD diagnosis were diagnosed during the first 6 years following DM1 diagnosis.
Conclusion
Screening asymptomatic DM1 patients for CD beyond 6 years after diagnosis is not recommended. Spontaneous normalization of CD serology occurs, and hence, serologic follow-up may be performed. In children with DM1 diagnosis under the age of 4.5 years or with positive CD serology at DM1 diagnosis, there is an increased risk for CD and therefore positive serology should lead to biopsy. |
doi_str_mv | 10.1007/s10620-018-5353-4 |
format | article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2127660610</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712937246</galeid><sourcerecordid>A712937246</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-a9c381dd78053d2ca24bec618692767f60725103669e9d9d4f6222f23503a06a3</originalsourceid><addsrcrecordid>eNp1kUuPFCEUhYnROD2tP8CNIbpxU-MFqqDKzaTt8ZWM0fiIS6ThVsukClqoXsy_H9pqNRoNC8jlOyfn5hDygMEZA1BPMwPJoQLWVo1oRFXfIgvWKFHxRra3yQKYLG_G5Ak5zfkKADrF5F1yIkAo1bZyQb6ucfDG0guf0WSkJjh6HK3C5DfReczUB3rxltH3ZvIYpvyMfvmGga4S0o82IQYftj-Uz33c5Wv6AW0cRwwO3fk9cqc3Q8b7x3tJPr988Wn9urp89-rNenVZ2Vq0U2U6K1rmnGqhEY5bw-sNWsla2XElVS9B8YaBkLLDznWu7iXnvOeiAWFAGrEkT2bfXYrf95gnPfpscRhMwLjPmrPiI0EWjyV59Bd6FfcplHSFqgXnDa8L9HiGtmZA7UMfp2TswVOvFOOdULyWhTr7B1WOw9HbGLD3Zf6HgM0Cm2LOCXu9S3406Voz0IdS9VyqLqXqQ6n6EOXhMe9-M6L7pfjZYgH4DOTyFbaYfi_0f9cbVyOnQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214322524</pqid></control><display><type>article</type><title>Celiac Disease and Celiac Antibodies in DM1 Patients: When Are Screening and Biopsy Recommended?</title><source>Springer Nature</source><creator>Slae, Mordechai ; Romem, Azi ; Edri, Shalom ; Toker, Ori ; Wilschanski, Michael ; Strich, David</creator><creatorcontrib>Slae, Mordechai ; Romem, Azi ; Edri, Shalom ; Toker, Ori ; Wilschanski, Michael ; Strich, David</creatorcontrib><description>Introduction
The prevalence of celiac disease (CD) is increased in diabetes mellitus type 1 (DM1) patients. In most cases, CD is diagnosed in asymptomatic patients and hence periodic screening tests are recommended, but the timing, frequency of tests and indication for duodenal biopsy is unclear. The purpose of this study was to investigate the dynamics of CD serology in DM1 and identify risk factors for CD.
Methods
Celiac serology and duodenal biopsy results from 1990 until 2015 were collected from patients with DM1. The outcome of positive celiac serology, the incidence and risk factors for CD in DM1 patients were investigated.
Results
A total of 314 DM1 patients who had celiac serology were identified, with follow-up period up to 23 years. Of 31 patients (9.9%) with positive celiac serology, 11(35.4%) had spontaneous normalization after various time periods. Eighteen patients were diagnosed with CD (58.1% of positive celiac serology, 5.73% of the study cohort). Age under 4.5 years was a risk factor for CD, but not family background of autoimmune diseases or gender. All patients with CD diagnosis were diagnosed during the first 6 years following DM1 diagnosis.
Conclusion
Screening asymptomatic DM1 patients for CD beyond 6 years after diagnosis is not recommended. Spontaneous normalization of CD serology occurs, and hence, serologic follow-up may be performed. In children with DM1 diagnosis under the age of 4.5 years or with positive CD serology at DM1 diagnosis, there is an increased risk for CD and therefore positive serology should lead to biopsy.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1007/s10620-018-5353-4</identifier><identifier>PMID: 30377886</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adolescent ; Adult ; Age Factors ; Antibodies ; Autoantibodies - immunology ; Biochemistry ; Biopsy ; Celiac disease ; Celiac Disease - diagnosis ; Celiac Disease - epidemiology ; Celiac Disease - immunology ; Celiac Disease - pathology ; Child ; Child, Preschool ; Cohort Studies ; Diabetes ; Diabetes Mellitus, Type 1 - epidemiology ; Duodenum - pathology ; Female ; Gastroenterology ; Gliadin - immunology ; GTP-Binding Proteins - immunology ; Health risk assessment ; Hepatology ; Humans ; Infant ; Male ; Mass Screening ; Medical research ; Medical screening ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Oncology ; Original Article ; Reticulin - immunology ; Retrospective Studies ; Serologic Tests ; Transglutaminases - immunology ; Transplant Surgery ; Viral antibodies ; Young Adult</subject><ispartof>Digestive diseases and sciences, 2019-02, Vol.64 (2), p.487-492</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><rights>COPYRIGHT 2019 Springer</rights><rights>Digestive Diseases and Sciences is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-a9c381dd78053d2ca24bec618692767f60725103669e9d9d4f6222f23503a06a3</citedby><cites>FETCH-LOGICAL-c438t-a9c381dd78053d2ca24bec618692767f60725103669e9d9d4f6222f23503a06a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30377886$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Slae, Mordechai</creatorcontrib><creatorcontrib>Romem, Azi</creatorcontrib><creatorcontrib>Edri, Shalom</creatorcontrib><creatorcontrib>Toker, Ori</creatorcontrib><creatorcontrib>Wilschanski, Michael</creatorcontrib><creatorcontrib>Strich, David</creatorcontrib><title>Celiac Disease and Celiac Antibodies in DM1 Patients: When Are Screening and Biopsy Recommended?</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><addtitle>Dig Dis Sci</addtitle><description>Introduction
The prevalence of celiac disease (CD) is increased in diabetes mellitus type 1 (DM1) patients. In most cases, CD is diagnosed in asymptomatic patients and hence periodic screening tests are recommended, but the timing, frequency of tests and indication for duodenal biopsy is unclear. The purpose of this study was to investigate the dynamics of CD serology in DM1 and identify risk factors for CD.
Methods
Celiac serology and duodenal biopsy results from 1990 until 2015 were collected from patients with DM1. The outcome of positive celiac serology, the incidence and risk factors for CD in DM1 patients were investigated.
Results
A total of 314 DM1 patients who had celiac serology were identified, with follow-up period up to 23 years. Of 31 patients (9.9%) with positive celiac serology, 11(35.4%) had spontaneous normalization after various time periods. Eighteen patients were diagnosed with CD (58.1% of positive celiac serology, 5.73% of the study cohort). Age under 4.5 years was a risk factor for CD, but not family background of autoimmune diseases or gender. All patients with CD diagnosis were diagnosed during the first 6 years following DM1 diagnosis.
Conclusion
Screening asymptomatic DM1 patients for CD beyond 6 years after diagnosis is not recommended. Spontaneous normalization of CD serology occurs, and hence, serologic follow-up may be performed. In children with DM1 diagnosis under the age of 4.5 years or with positive CD serology at DM1 diagnosis, there is an increased risk for CD and therefore positive serology should lead to biopsy.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Antibodies</subject><subject>Autoantibodies - immunology</subject><subject>Biochemistry</subject><subject>Biopsy</subject><subject>Celiac disease</subject><subject>Celiac Disease - diagnosis</subject><subject>Celiac Disease - epidemiology</subject><subject>Celiac Disease - immunology</subject><subject>Celiac Disease - pathology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cohort Studies</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 1 - epidemiology</subject><subject>Duodenum - pathology</subject><subject>Female</subject><subject>Gastroenterology</subject><subject>Gliadin - immunology</subject><subject>GTP-Binding Proteins - immunology</subject><subject>Health risk assessment</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Mass Screening</subject><subject>Medical research</subject><subject>Medical screening</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Reticulin - immunology</subject><subject>Retrospective Studies</subject><subject>Serologic Tests</subject><subject>Transglutaminases - immunology</subject><subject>Transplant Surgery</subject><subject>Viral antibodies</subject><subject>Young Adult</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kUuPFCEUhYnROD2tP8CNIbpxU-MFqqDKzaTt8ZWM0fiIS6ThVsukClqoXsy_H9pqNRoNC8jlOyfn5hDygMEZA1BPMwPJoQLWVo1oRFXfIgvWKFHxRra3yQKYLG_G5Ak5zfkKADrF5F1yIkAo1bZyQb6ucfDG0guf0WSkJjh6HK3C5DfReczUB3rxltH3ZvIYpvyMfvmGga4S0o82IQYftj-Uz33c5Wv6AW0cRwwO3fk9cqc3Q8b7x3tJPr988Wn9urp89-rNenVZ2Vq0U2U6K1rmnGqhEY5bw-sNWsla2XElVS9B8YaBkLLDznWu7iXnvOeiAWFAGrEkT2bfXYrf95gnPfpscRhMwLjPmrPiI0EWjyV59Bd6FfcplHSFqgXnDa8L9HiGtmZA7UMfp2TswVOvFOOdULyWhTr7B1WOw9HbGLD3Zf6HgM0Cm2LOCXu9S3406Voz0IdS9VyqLqXqQ6n6EOXhMe9-M6L7pfjZYgH4DOTyFbaYfi_0f9cbVyOnQA</recordid><startdate>20190215</startdate><enddate>20190215</enddate><creator>Slae, Mordechai</creator><creator>Romem, Azi</creator><creator>Edri, Shalom</creator><creator>Toker, Ori</creator><creator>Wilschanski, Michael</creator><creator>Strich, David</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190215</creationdate><title>Celiac Disease and Celiac Antibodies in DM1 Patients: When Are Screening and Biopsy Recommended?</title><author>Slae, Mordechai ; Romem, Azi ; Edri, Shalom ; Toker, Ori ; Wilschanski, Michael ; Strich, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-a9c381dd78053d2ca24bec618692767f60725103669e9d9d4f6222f23503a06a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Antibodies</topic><topic>Autoantibodies - immunology</topic><topic>Biochemistry</topic><topic>Biopsy</topic><topic>Celiac disease</topic><topic>Celiac Disease - diagnosis</topic><topic>Celiac Disease - epidemiology</topic><topic>Celiac Disease - immunology</topic><topic>Celiac Disease - pathology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cohort Studies</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 1 - epidemiology</topic><topic>Duodenum - pathology</topic><topic>Female</topic><topic>Gastroenterology</topic><topic>Gliadin - immunology</topic><topic>GTP-Binding Proteins - immunology</topic><topic>Health risk assessment</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Mass Screening</topic><topic>Medical research</topic><topic>Medical screening</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Reticulin - immunology</topic><topic>Retrospective Studies</topic><topic>Serologic Tests</topic><topic>Transglutaminases - immunology</topic><topic>Transplant Surgery</topic><topic>Viral antibodies</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Slae, Mordechai</creatorcontrib><creatorcontrib>Romem, Azi</creatorcontrib><creatorcontrib>Edri, Shalom</creatorcontrib><creatorcontrib>Toker, Ori</creatorcontrib><creatorcontrib>Wilschanski, Michael</creatorcontrib><creatorcontrib>Strich, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Slae, Mordechai</au><au>Romem, Azi</au><au>Edri, Shalom</au><au>Toker, Ori</au><au>Wilschanski, Michael</au><au>Strich, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Celiac Disease and Celiac Antibodies in DM1 Patients: When Are Screening and Biopsy Recommended?</atitle><jtitle>Digestive diseases and sciences</jtitle><stitle>Dig Dis Sci</stitle><addtitle>Dig Dis Sci</addtitle><date>2019-02-15</date><risdate>2019</risdate><volume>64</volume><issue>2</issue><spage>487</spage><epage>492</epage><pages>487-492</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><abstract>Introduction
The prevalence of celiac disease (CD) is increased in diabetes mellitus type 1 (DM1) patients. In most cases, CD is diagnosed in asymptomatic patients and hence periodic screening tests are recommended, but the timing, frequency of tests and indication for duodenal biopsy is unclear. The purpose of this study was to investigate the dynamics of CD serology in DM1 and identify risk factors for CD.
Methods
Celiac serology and duodenal biopsy results from 1990 until 2015 were collected from patients with DM1. The outcome of positive celiac serology, the incidence and risk factors for CD in DM1 patients were investigated.
Results
A total of 314 DM1 patients who had celiac serology were identified, with follow-up period up to 23 years. Of 31 patients (9.9%) with positive celiac serology, 11(35.4%) had spontaneous normalization after various time periods. Eighteen patients were diagnosed with CD (58.1% of positive celiac serology, 5.73% of the study cohort). Age under 4.5 years was a risk factor for CD, but not family background of autoimmune diseases or gender. All patients with CD diagnosis were diagnosed during the first 6 years following DM1 diagnosis.
Conclusion
Screening asymptomatic DM1 patients for CD beyond 6 years after diagnosis is not recommended. Spontaneous normalization of CD serology occurs, and hence, serologic follow-up may be performed. In children with DM1 diagnosis under the age of 4.5 years or with positive CD serology at DM1 diagnosis, there is an increased risk for CD and therefore positive serology should lead to biopsy.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>30377886</pmid><doi>10.1007/s10620-018-5353-4</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0163-2116 |
ispartof | Digestive diseases and sciences, 2019-02, Vol.64 (2), p.487-492 |
issn | 0163-2116 1573-2568 |
language | eng |
recordid | cdi_proquest_miscellaneous_2127660610 |
source | Springer Nature |
subjects | Adolescent Adult Age Factors Antibodies Autoantibodies - immunology Biochemistry Biopsy Celiac disease Celiac Disease - diagnosis Celiac Disease - epidemiology Celiac Disease - immunology Celiac Disease - pathology Child Child, Preschool Cohort Studies Diabetes Diabetes Mellitus, Type 1 - epidemiology Duodenum - pathology Female Gastroenterology Gliadin - immunology GTP-Binding Proteins - immunology Health risk assessment Hepatology Humans Infant Male Mass Screening Medical research Medical screening Medicine Medicine & Public Health Medicine, Experimental Oncology Original Article Reticulin - immunology Retrospective Studies Serologic Tests Transglutaminases - immunology Transplant Surgery Viral antibodies Young Adult |
title | Celiac Disease and Celiac Antibodies in DM1 Patients: When Are Screening and Biopsy Recommended? |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T01%3A49%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Celiac%20Disease%20and%20Celiac%20Antibodies%20in%20DM1%20Patients:%20When%20Are%20Screening%20and%20Biopsy%20Recommended?&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=Slae,%20Mordechai&rft.date=2019-02-15&rft.volume=64&rft.issue=2&rft.spage=487&rft.epage=492&rft.pages=487-492&rft.issn=0163-2116&rft.eissn=1573-2568&rft_id=info:doi/10.1007/s10620-018-5353-4&rft_dat=%3Cgale_proqu%3EA712937246%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c438t-a9c381dd78053d2ca24bec618692767f60725103669e9d9d4f6222f23503a06a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=214322524&rft_id=info:pmid/30377886&rft_galeid=A712937246&rfr_iscdi=true |